دورية أكاديمية
أعرض في EDS

Phenolic diterpenes from Rosemary supercritical extract inhibit non-small cell lung cancer lipid metabolism and synergise with therapeutic drugs in the clinic.

التفاصيل البيبلوغرافية
العنوان: Phenolic diterpenes from Rosemary supercritical extract inhibit non-small cell lung cancer lipid metabolism and synergise with therapeutic drugs in the clinic.
المؤلفون: Bouzas A; Precision Nutrition and Cancer Program, Molecular Oncology Group, IMDEA Food Institute, CEI UAM, CSIC, Madrid, Spain.; CANAAN Research & Investment Group, Madrid, Spain., Gómez de Cedrón M; Precision Nutrition and Cancer Program, Molecular Oncology Group, IMDEA Food Institute, CEI UAM, CSIC, Madrid, Spain., Colmenarejo G; Biostatistics and Bioinformatics Unit, IMDEA Food Institute, CEI UAM, CSIC, Madrid, Spain., Laparra-Llopis JM; Molecular Immuno-Nutrition Group, IMDEA-Food Institute, CEI UAM, CSIC, Madrid, Spain., Moreno-Rubio J; Precision Nutrition and Cancer Program, Molecular Oncology Group, IMDEA Food Institute, CEI UAM, CSIC, Madrid, Spain.; Medical Oncology Department, Infanta Sofía University Hospital, San Sebastián de los Reyes, Madrid, Spain., Montoya JJ; CANAAN Research & Investment Group, Madrid, Spain.; Faculty of Medicine, Complutense University of Madrid, Madrid, Spain., Reglero G; Precision Nutrition and Cancer Program, Molecular Oncology Group, IMDEA Food Institute, CEI UAM, CSIC, Madrid, Spain.; Department of Production and Characterization of Novel Foods, Institute of Food Science Research (CIAL) (CSIC.UAM), Madrid, Spain., Casado E; Medical Oncology Department, Infanta Sofía University Hospital, San Sebastián de los Reyes, Madrid, Spain., Tabares B; Medical Oncology Department, Infanta Sofía University Hospital, San Sebastián de los Reyes, Madrid, Spain., Sereno M; Medical Oncology Department, Infanta Sofía University Hospital, San Sebastián de los Reyes, Madrid, Spain., Ramírez de Molina A; Precision Nutrition and Cancer Program, Molecular Oncology Group, IMDEA Food Institute, CEI UAM, CSIC, Madrid, Spain.
المصدر: Frontiers in oncology [Front Oncol] 2022 Nov 09; Vol. 12, pp. 1046369. Date of Electronic Publication: 2022 Nov 09 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مستخلص: Lung cancer is one of the most deadly and common cancers in the world. The molecular features of patient's tumours dictate the different therapeutic decisions, which combines targeted therapy, chemotherapy, and immunotherapy. Altered cellular metabolism is one of the hallmarks of cancer. Tumour cells reprogram their metabolism to adapt to their novel requirements of growth, proliferation, and survival. Together with the Warburg effect, the role of lipid metabolism alterations in cancer development and prognosis has been highlighted. Several lipid related genes have been shown to promote transformation and progression of cancer cells and have been proposed as biomarkers for prognosis. Nevertheless, the exact mechanisms of the regulation of lipid metabolism and the biological consequences in non-small cell lung cancer (NSCLC) have not been elucidated yet. There is an urgent necessity to develop multidisciplinary and complementary strategies to improve NSCLC patients´ well-being and treatment response. Nutrients can directly affect fundamental cellular processes and some diet-derived ingredients, bioactive natural compounds and natural extracts have been shown to inhibit the tumour growth in preclinical and clinical trials. Previously, we described a supercritical extract of rosemary (SFRE) (12 - 16% composition of phenolic diterpenes carnosic acid and carnosol) as a potential antitumoral agent in colon and breast cancer due to its effects on the inhibition of lipid metabolism and DNA synthesis, and in the reduction of resistance to 5-FluoroUracil (5-FU). Herein, we demonstrate SFRE inhibits NSCLC cell bioenergetics identifying several lipid metabolism implicated targets. Moreover, SFRE synergises with standard therapeutic drugs used in the clinic, such as cisplatin, pemetrexed and pembrolizumab to inhibit of cell viability of NSCLC cells. Importantly, the clinical relevance of SFRE as a complement in the treatment of NSCLC patients is suggested based on the results of a pilot clinical trial where SFRE formulated with bioactive lipids (PCT/ES2017/070263) diminishes metabolic and inflammatory targets in peripheral-blood mononuclear cells (PBMC), such as MAPK (p=0.04) , NLRP3 (p=0.044) , and SREBF1 (p=0.047) , which may augment the immune antitumour function. Based on these results, SFRE merits further investigation as a co-adjuvant in the treatment of NSCLC.
Clinical Trial Registration: ClinicalTrials.gov Identifier NCT05080920.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2022 Bouzas, Gómez de Cedrón, Colmenarejo, Laparra-Llopis, Moreno-Rubio, Montoya, Reglero, Casado, Tabares, Sereno and Ramírez de Molina.)
References: J Immunol Res. 2018 Apr 11;2018:5708239. (PMID: 29850632)
Front Oncol. 2020 Oct 28;10:577420. (PMID: 33194695)
J Natl Cancer Inst. 1991 Jun 5;83(11):757-66. (PMID: 2041050)
Signal Transduct Target Ther. 2019 Dec 17;4:61. (PMID: 31871778)
Nature. 2018 Jan 24;553(7689):446-454. (PMID: 29364287)
Nat Commun. 2019 Nov 1;10(1):5011. (PMID: 31676791)
J Exp Clin Cancer Res. 2020 Aug 31;39(1):176. (PMID: 32867817)
Nutrients. 2017 Sep 28;9(10):. (PMID: 28956850)
Histochemistry. 1992 Jul;97(6):493-7. (PMID: 1385366)
Nutr Rev. 2013 Sep;71(9):585-99. (PMID: 24032363)
Proc Natl Acad Sci U S A. 2013 May 28;110(22):8882-7. (PMID: 23671091)
Mol Oncol. 2018 Oct;12(10):1735-1752. (PMID: 30098223)
Int J Oncol. 2015 May;46(5):2083-95. (PMID: 25695284)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Front Immunol. 2018 Dec 14;9:2927. (PMID: 30619288)
Clin Lung Cancer. 2016 Jul;17(4):263-270.e2. (PMID: 26707383)
Cells. 2020 Nov 07;9(11):. (PMID: 33171828)
Cancer Lett. 2021 Mar 1;500:75-86. (PMID: 33347908)
Front Immunol. 2018 Jul 30;9:1774. (PMID: 30105035)
Electrophoresis. 2014 Jun;35(11):1719-27. (PMID: 24615943)
Nat Med. 2010 Aug;16(8):880-6. (PMID: 20622859)
Crit Rev Oncol Hematol. 2017 Apr;112:31-40. (PMID: 28325263)
N Engl J Med. 2010 Jun 24;362(25):2380-8. (PMID: 20573926)
Oncotarget. 2017 Dec 14;8(69):114292-114299. (PMID: 29371987)
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6640-6650. (PMID: 32161124)
CA Cancer J Clin. 2019 Jan;69(1):7-34. (PMID: 30620402)
Interdiscip Sci. 2019 Jun;11(2):266-272. (PMID: 31098955)
Oncotarget. 2017 Dec 21;9(5):5919-5930. (PMID: 29464044)
Lung Cancer. 2020 Jan;139:195-199. (PMID: 31812890)
FASEB J. 2020 Aug;34(8):10574-10589. (PMID: 32568455)
Cancer Med. 2017 Aug;6(8):1965-1975. (PMID: 28719077)
PLoS One. 2014 Jun 03;9(6):e98556. (PMID: 24892299)
Oncol Rep. 2016 Apr;35(4):2053-64. (PMID: 26782741)
Nat Rev Cancer. 2013 Apr;13(4):227-32. (PMID: 23446547)
Clin Cancer Res. 2019 Aug 1;25(15):4592-4602. (PMID: 30824587)
J Agric Food Chem. 2013 Mar 20;61(11):2803-10. (PMID: 23432097)
Mol Oncol. 2020 Dec;14(12):3135-3152. (PMID: 33030783)
Curr Med Chem. 2020;27(32):5274-5316. (PMID: 30854949)
Cancer Res. 2010 Jan 15;70(2):440-6. (PMID: 20068163)
Pharmacol Res. 2013 Jun;72:61-8. (PMID: 23557932)
Cancer Res. 2009 Apr 15;69(8):3256-61. (PMID: 19351834)
Phytomedicine. 2020 Jan;66:153109. (PMID: 31790894)
Cell Rep. 2016 Aug 9;16(6):1614-1628. (PMID: 27477280)
Invest New Drugs. 2011 Oct;29(5):883-90. (PMID: 20467885)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Cancer. 2020 Jan 15;126(2):260-270. (PMID: 31691957)
Cancer Lett. 2017 Oct 10;406:93-104. (PMID: 28797843)
Cancer Immunol Res. 2017 Feb;5(2):94-99. (PMID: 28093447)
Nutrients. 2019 Aug 24;11(9):. (PMID: 31450563)
Nutr Cancer. 2015;67(8):1221-9. (PMID: 26452641)
Sci Rep. 2018 May 31;8(1):8485. (PMID: 29855486)
PLoS One. 2016 May 12;11(5):e0155660. (PMID: 27171439)
Trends Cancer. 2019 Nov;5(11):693-703. (PMID: 31735288)
Oncol Rep. 2018 Nov;40(5):2674-2682. (PMID: 30132556)
PLoS One. 2015 Apr 17;10(4):e0123563. (PMID: 25886502)
Surg Oncol Clin N Am. 2020 Jan;29(1):15-21. (PMID: 31757310)
Cancer Commun (Lond). 2019 Jul 15;39(1):43. (PMID: 31307548)
Lancet Respir Med. 2017 Sep;5(9):669-671. (PMID: 28734820)
Mol Clin Oncol. 2019 Jan;10(1):137-143. (PMID: 30655989)
Clin Cancer Res. 2000 Jul;6(7):2677-84. (PMID: 10914709)
Mol Immunol. 2007 Apr;44(11):2850-9. (PMID: 17328955)
فهرسة مساهمة: Keywords: NSCLC; lipid metabolism; phenolic diterpenes; precision nutrition; rosemary extract
سلسلة جزيئية: ClinicalTrials.gov NCT05080920
تواريخ الأحداث: Date Created: 20221128 Latest Revision: 20221129
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC9682134
DOI: 10.3389/fonc.2022.1046369
PMID: 36439419
قاعدة البيانات: MEDLINE
الوصف
تدمد:2234-943X
DOI:10.3389/fonc.2022.1046369